NXY-059 is a neuroprotective agent developed primarily for the treatment of acute ischemic stroke. It functions as a free radical scavenger, targeting reactive oxygen species that contribute to neuronal damage following cerebral ischemia. By neutralizing these radicals, NXY-059 helps reduce oxidative stress in brain tissue, thereby limiting the extent of cell death and infarct size during the critical period after stroke onset. The compound was investigated in clinical trials to evaluate its ability to improve neurological outcomes when administered soon after stroke. It showed promise in preclinical studies, where it demonstrated the ability to cross the blood-brain barrier and provide protection in animal models of stroke. However, large-scale clinical trials did not demonstrate significant functional improvement in patients, leading to discontinuation of its development for stroke treatment. Despite the lack of success in stroke, the mechanism of action of NXY-059 has contributed to ongoing research into antioxidant-based therapies for neurodegenerative conditions and other central nervous system injuries involving oxidative damage.